EMA Authorised: Fycompa (perampanel) — Eisai GmbH

View source ↗

Summary

The EMA authorises Fycompa (perampanel) for partial epilepsies in Europe, with Eisai GmbH as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Partial Epilepsy

Drugs mentioned

• Fycompa (perampanel)

Snippet

Status: Authorised. Therapeutic area: Epilepsies, Partial. MAH: Eisai GmbH. Decision date: 21/05/2026